BACKGROUND AND PURPOSE: Ureteroscopy (URS) is a common treatment for patients with stone disease. One of the disadvantages of this approach is the great capital expense associated with the purchase and repair of endoscopic equipment. In some cases, these costs can outpace revenues and lead to an unprofitable and unsustainable enterprise. We sought to characterize the profitability of our URS program when accounting for endoscope maintenance and repair costs. MATERIALS AND METHODS: We identified all URS cases performed at a single hospital during fiscal year 2013 (FY2013). Charges, collection rates, and fixed and variable costs including annual equipment repair costs were obtained. The net margin and break-even point of URS were derived on a per-case basis. RESULTS: For 190 cases performed in FY2013, total endoscope repair costs totaled $115,000, resulting in an average repair cost of $605 per case. The vast majority of cases (94.2%) were conducted in the outpatient setting, which generated a net margin of $659 per case, while inpatient cases yielded a net loss of $455. URS was ultimately associated with a net positive margin approaching $600 per case. On break-even analysis, URS remained profitable until repair costs reached $1200 per case. CONCLUSIONS: Based on these findings, an established URS program can sustain profitability even with large equipment repair costs. Nonetheless, our findings serve to emphasize the importance of controlling costs, particularly in the current setting of decreasing reimbursement. A multifaceted approach, based on improving endoscope durability and exploring digital and disposable platforms, will be critical in maintaining the sustainability of URS.
BACKGROUND AND PURPOSE: Ureteroscopy (URS) is a common treatment for patients with stone disease. One of the disadvantages of this approach is the great capital expense associated with the purchase and repair of endoscopic equipment. In some cases, these costs can outpace revenues and lead to an unprofitable and unsustainable enterprise. We sought to characterize the profitability of our URS program when accounting for endoscope maintenance and repair costs. MATERIALS AND METHODS: We identified all URS cases performed at a single hospital during fiscal year 2013 (FY2013). Charges, collection rates, and fixed and variable costs including annual equipment repair costs were obtained. The net margin and break-even point of URS were derived on a per-case basis. RESULTS: For 190 cases performed in FY2013, total endoscope repair costs totaled $115,000, resulting in an average repair cost of $605 per case. The vast majority of cases (94.2%) were conducted in the outpatient setting, which generated a net margin of $659 per case, while inpatient cases yielded a net loss of $455. URS was ultimately associated with a net positive margin approaching $600 per case. On break-even analysis, URS remained profitable until repair costs reached $1200 per case. CONCLUSIONS: Based on these findings, an established URS program can sustain profitability even with large equipment repair costs. Nonetheless, our findings serve to emphasize the importance of controlling costs, particularly in the current setting of decreasing reimbursement. A multifaceted approach, based on improving endoscope durability and exploring digital and disposable platforms, will be critical in maintaining the sustainability of URS.
Authors: Dylan Isaacson; Tessnim Ahmad; Ian Metzler; David T Tzou; Kazumi Taguchi; Manint Usawachintachit; Samuel Zetumer; Benjamin Sherer; Marshall Stoller; Thomas Chi Journal: J Endourol Date: 2017-09-20 Impact factor: 2.942
Authors: Kazumi Taguchi; Jonathan D Harper; Marshall L Stoller; Brian D Duty; Mathew D Sorensen; Roger L Sur; Manint Usawachintachit; David T Tzou; David L Wenzler; Dylan Isaacson; Angela Xu; Carissa Chu; Uwais B Zaid; Eric R Taylor; Krishna Ramaswamy; Thomas Chi Journal: Urolithiasis Date: 2017-12-09 Impact factor: 3.436
Authors: Steeve Doizi; Guido Kamphuis; Guido Giusti; Kim Hovgaard Andreassen; Thomas Knoll; Palle Jörn Osther; Cesare Scoffone; Daniel Pérez-Fentes; Silvia Proietti; Oliver Wiseman; Jean de la Rosette; Olivier Traxer Journal: World J Urol Date: 2016-09-26 Impact factor: 4.226
Authors: Charles D Scales; Jonathan Bergman; Stacey Carter; Gregory Jack; Christopher S Saigal; Mark S Litwin Journal: Urology Date: 2015-09-01 Impact factor: 2.649